Artificial intelligence is transforming one of drug development's biggest bottlenecks: finding enough eligible patients willing to participate in clinical trials. Rather than replacing researchers, AI tools are helping them identify potential participants faster, streamline study design, and reduce enrollment timelines that can stretch from months to several years.

What's the Real Challenge in Clinical Trial Recruitment?

Patient enrollment sits at the intersection of science, healthcare delivery, and human behavior. On the surface, matching people with a particular condition to relevant studies seems straightforward. In reality, prospective participants must meet specific eligibility criteria, know the trial exists, have access to a participating research site, and be able to commit to required visits and procedures.

The recruitment timeline varies dramatically depending on the study type. Seasonal vaccine trials might recruit participants in a few months, while oncology, rare disease, or pediatric studies can take three years or longer simply to enroll enough volunteers. For patients waiting for potential new treatments, those delays matter significantly.

"We run clinical trials to create meaningful results that ultimately lead to regulatory submissions and, hopefully, life-changing treatments for patients. Any delay pushes that process and potential progress further back," said Melinda Rottas, Vice President and Head of Optimization, Analytics and Recruitment Solutions at Pfizer.

Melinda Rottas, Vice President, Head of Optimization, Analytics and Recruitment Solutions at Pfizer

How Is AI Speeding Up Patient Matching?

Today, clinical trial site staff typically review patient charts manually and make phone calls to identify potentially eligible participants. AI is automating this labor-intensive process by scanning electronic health records and flagging candidates who meet study criteria, allowing researchers to spend less time searching and more time connecting eligible patients with opportunities.

The technology also helps earlier in the trial lifecycle. Before a study even launches, AI can assist with protocol development by drafting portions of study documents and flagging whether trial designs might place unnecessary burdens on participants. Once a protocol is finalized, AI can identify optimal research sites by analyzing disease prevalence, historical enrollment patterns, healthcare infrastructure, and standard-of-care practices.

Beyond site selection, AI has potential to streamline the complex process of activating research locations, coordinating regulatory approvals, training investigators, and ensuring study medication reaches participating sites more efficiently.

Steps to Implement AI-Driven Patient Matching in Clinical Trials

• Protocol Optimization: Use AI to draft study documents and evaluate whether trial designs create unnecessary participant burden before launching recruitment.
• Site Selection and Activation: Deploy AI to identify optimal research locations based on disease prevalence and historical data, then streamline regulatory approvals and investigator training.
• Automated Patient Identification: Implement AI systems that scan electronic health records to flag potentially eligible participants, reducing manual chart review by clinical staff.
• Community Outreach Tailoring: Use AI to identify where specific patient populations receive care and customize recruitment strategies for underrepresented communities.
• Human-in-the-Loop Verification: Ensure clinicians and principal investigators review AI recommendations and make final eligibility determinations before patient enrollment.

Why Human Oversight Remains Essential?

A common misconception is that AI will replace physicians and researchers. According to Pfizer's Rottas, the reality is quite different. AI functions as a thought partner that automates repetitive tasks, generates documents, and surfaces insights, but humans consume that information and make the final decisions.

"We talk a lot about having a 'human in the loop,' or even 'human at the helm.' AI can be a great thought partner. It can help with research, automate repetitive tasks, generate documents, and surface insights. But there is always a person consuming that information and making the decisions," Rottas explained.

Melinda Rottas, Vice President, Head of Optimization, Analytics and Recruitment Solutions at Pfizer

Even when AI identifies someone who appears eligible for a clinical trial, the technology doesn't decide whether they participate. Prospective participants must still sign informed consent, undergo a robust screening process, and receive final approval from the principal investigator or study doctor.

Could AI Expand Access to Underrepresented Populations?

Historically, researchers selected trial sites based largely on previous enrollment performance. AI-enabled patient matching offers a different approach by identifying where eligible patients actually receive care, potentially uncovering opportunities that traditional recruitment methods miss.

This capability could help address long-standing disparities in clinical research. AI can identify barriers to participation and tailor outreach strategies to different communities, making trial opportunities more visible and accessible for people who have historically been underrepresented in research.

However, technology alone cannot build trust. Anyone considering a clinical trial is making a significant decision. Trust is built through community engagement, partnerships with patient advocacy organizations, listening to patient feedback, and ensuring research reflects the needs of the communities it serves.

What's Driving Growth in AI-Powered Drug Formulation?

Beyond patient recruitment, AI is reshaping how drugs are formulated. The global AI-powered drug formulation market was valued at $782.60 million in 2025 and is projected to reach $4,431.11 million by 2033, growing at a compound annual growth rate of 24.20%.

This expansion is driven by several factors. Pharmaceutical companies are increasingly adopting AI and machine learning to accelerate drug development, optimize drug efficacy and safety, and improve stability and bioavailability. The growing complexity of drug formulation, combined with the need to develop personalized therapies, is compelling pharmaceutical firms and contract research organizations to integrate AI into their workflows.

North America dominated the AI-powered drug formulation market with 44.24% of revenue share in 2025, supported by a strong pharmaceutical ecosystem and substantial AI investment. Asia-Pacific is expected to be the fastest-growing region at a compound annual growth rate of 28.31% from 2026 to 2033, fueled by pharmaceutical digitalization and expanding capabilities in China, India, South Korea, and Japan.

Within the market, small molecules led with 40.14% share in 2025, while biologics are the fastest-growing drug type, projected to register a compound annual growth rate of 27.26%, reflecting the surge in complexity of biologic formulation development. Software platforms dominated the component category with 51% of revenue share, driven by increasing demand for AI-enabled tools for formulation prediction and optimization.

The excipient compatibility prediction segment is the fastest-growing application category, with a compound annual growth rate of 26.03%, as pharmaceutical companies seek to identify suitable excipients more efficiently during formulation development.